 |
|
New approach to gene therapy may shrink brain tumors, prevent their spread
September 26, 2008Massachusetts General Hospital (MGH) researchers are investigating a new approach to gene therapy for brain tumors - delivering a cancer-fighting gene to normal brain tissue around the tumor to keep it from spreading. An animal study published in the journal Molecular Therapy, the first to test the feasibility of such an approach, found that inducing mouse brain cells to secrete human interferon-beta suppressed and eliminated growth of human glioblastoma cells implanted nearby.
"We had hypothesized that genetically engineering normal tissue surrounding a tumor could create a zone of resistance - a microenvironment that prevents the growth or spread of the tumor," says Miguel Sena-Esteves, PhD, of the MGH Neuroscience Center, the study's senior author. "This proof of principle study shows that this could be a highly effective approach, although there are many additional questions that need to be investigated."
Glioblastoma is the most common and deadly form of brain tumor. Human clinical trials of other gene therapies have not significantly reduced tumor progression. One problem has been that patients' immune systems target the viral vectors used to deliver cancer-eliminating genes. Another issue has been inefficient gene delivery, due in part to the inherent cellular diversity found within an individual patient's tumor as well as among tumors from different patients. In addition, if tumor cells are successfully induced to express an anticancer protein, production of that protein will drop as the tumor dies, allowing any cells that did not receive the gene to resume growing. In the current study the MGH team examined whether expression of a therapeutic gene in normal brain cells could form a stable and effective anti-tumor reservoir.
The researchers first pretreated immune-deficient mice by delivering a gene for human interferon-beta - a protein being tested against several types of cancer - into the animals' brains using adeno-associated virus vectors known to effectively deliver genes to neurons in the brain without the immune reaction produced by other vectors. Two weeks later, human glioblastoma cells were injected into the same or adjacent areas of the animal's brains. After only four days, mice expressing interferon-beta had significantly smaller tumors than did a control group pretreated with gene-free vector. Two weeks after the glioblastoma cells were introduced, the tumors had completely disappeared from the brains of the gene-therapy-treated mice.
Several additional experiments verified that the anti-tumor effect was produced by expression of interferon-beta in normal tissue. The same tumor growth suppression was seen when the genes were delivered to one side of the brain and tumor cells were injected into the other. Using a specialized vector that allows genes to be expressed only in neuronal cells and not the glial cells from which glioblastomas originate also produced similar results. While other gene therapy studies that have induced tumor regression in mouse models required several vector injections, these experiments were able to suppress growth and eliminate the implanted tumor with a single injection of the interferon-beta-encoding vector, underscoring the approach's effectiveness.
"These results are particularly important as we build on our understanding of the microenvironments that allow tumors to grow and spread," explains Sena-Esteves, an assistant professor of Neurology at Harvard Medical School. "The therapeutic principle of genetically engineering normal brain tissue could be used to manipulate proteins required for that microenvironment, preventing tumors from migrating within the patients brain and escaping other therapies." The same zone-of-resistance approach could also be applied to the treatment of other solid tumors, he notes.
Since interferon-beta treatment is known to have side effects, it will be important to identify any toxicity caused by long term secretion of the protein in the brain and develop preventive strategies, such as turning off the introduced genes. Next the MGH team is planning to test this strategy on glioblastomas that occur naturally in dogs, which could not only generate additional data supporting human trials but also develop veterinary treatments for canine patients.
Massachusetts General Hospital
The researchers first pretreated immune-deficient mice by delivering a gene for human interferon-beta - a protein being tested against several types of cancer - into the animals' brains using adeno-associated virus vectors known to effectively deliver genes to neurons in the brain without the immune reaction produced by other vectors. Two weeks later, human glioblastoma cells were injected into the same or adjacent areas of the animal's brains. After only four days, mice expressing interferon-beta had significantly smaller tumors than did a control group pretreated with gene-free vector. Two weeks after the glioblastoma cells were introduced, the tumors had completely disappeared from the brains of the gene-therapy-treated mice.
Several additional experiments verified that the anti-tumor effect was produced by expression of interferon-beta in normal tissue. The same tumor growth suppression was seen when the genes were delivered to one side of the brain and tumor cells were injected into the other. Using a specialized vector that allows genes to be expressed only in neuronal cells and not the glial cells from which glioblastomas originate also produced similar results. While other gene therapy studies that have induced tumor regression in mouse models required several vector injections, these experiments were able to suppress growth and eliminate the implanted tumor with a single injection of the interferon-beta-encoding vector, underscoring the approach's effectiveness.
"These results are particularly important as we build on our understanding of the microenvironments that allow tumors to grow and spread," explains Sena-Esteves, an assistant professor of Neurology at Harvard Medical School. "The therapeutic principle of genetically engineering normal brain tissue could be used to manipulate proteins required for that microenvironment, preventing tumors from migrating within the patients brain and escaping other therapies." The same zone-of-resistance approach could also be applied to the treatment of other solid tumors, he notes.
Since interferon-beta treatment is known to have side effects, it will be important to identify any toxicity caused by long term secretion of the protein in the brain and develop preventive strategies, such as turning off the introduced genes. Next the MGH team is planning to test this strategy on glioblastomas that occur naturally in dogs, which could not only generate additional data supporting human trials but also develop veterinary treatments for canine patients.
Massachusetts General Hospital
Gene Therapy Current Events and Gene Therapy News RSSGene therapy corrects sickle cell disease in laboratory study
Using a harmless virus to insert a corrective gene into mouse blood cells, scientists at St. Jude Children's Research Hospital have alleviated sickle cell disease pathology.
Science teams at Cold Spring Harbor Laboratory identify 13 new tumor-suppressor genes in liver cancer
Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise. At Cold Spring Harbor Laboratory (CSHL), five different research groups have now combined their expertise to speed up the rate of discovering cancer-related genes and validating their function in living animals.
New gene silencing pathway found in plants
Biologists at Washington University in St. Louis have made major headway in explaining a mechanism by which plant cells silence potentially harmful genes.
First trial of gene therapy for advanced heart failure shows promising results
Phase I results of the first clinical trial of gene therapy for patients with advanced heart failure show the approach to be promising, with improvements in several measures of the condition's severity.
Researchers use chemical from medicinal plants to fight HIV
Like other kinds of cells, immune cells lose the ability to divide as they age because a part of their chromosomes known as a telomere becomes progressively shorter with cell division. As a result, the cell changes in many ways, and its disease fighting ability is compromised.
A double-barreled immune cell approach for neuroblastoma
Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online today in the journal Nature Medicine.
Scientist clears hurdles for muscular dystrophy therapy
Approximately 250,000 people in the United States have some form of muscular dystrophy. Duchenne muscular dystrophy (DMD) is the most common type of the disease, predominantly affecting males.
Study may explain exercise-induced fatigue in muscular dystrophies
A University of Iowa study suggests that the prolonged fatigue after mild exercise that occurs in people with many forms of muscular dystrophy is distinct from the inherent muscle weakness caused by the disease.
MicroRNAs make for safer cancer treatments
Viruses -- long regarded solely as disease agents -- now are being used in therapies for cancer. Concerns over the safety of these so-called oncolytic viruses stem from their potential to damage healthy tissues.
Keeping herpes infection in check: Pitt researchers describe immune system strategies
Herpes simplex virus type I can cause bouts of cold sores, blindness and potentially lethal encephalitis when it reawakens from a quiescent state in the nerve cells it infects.
More Gene Therapy Current Events and Gene Therapy News Articles
 | Animal Cell Technology: From Biopharmaceuticals to Gene Therapy by Leda Castilho: "Animal Cell Technology: from Biopharmaceuticals to Gene Therapy" provides a comprehensive insight into biological and engineering concepts related to mammalian and insect cell technology, as well as an overview of the applications of animal cell technology. Part 1 of the book covers the Fundamentals upon which this technology is based and covers the science underpinning the technology. Part 2... |
 | Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Third Edition This latest edition of Gene and Cell Therapy provides comprehensive coverage of all aspects of the tools and state-of-the-art technologies that are currently available in this field. Written by international leaders, this third edition features 12 additional chapters that address such new topics as gene and cell therapies for diabetes and cardiovascular disease, relevant nanotechnologies, siRNA... |
 | Gene Therapy: Treating Disease by Repairing Genes (New Biology) by Joseph, Ph.D. Panno Many diseases are caused by a simple point mutation - they are the result of a single defective gene. Gene therapy is the attempt to replace a defective gene with a good copy or to add a good gene to compensate for the bad. Although this procedure has proven to be extremely hazardous, of all the technologies provided by the new biology, gene therapy holds much potential for curing disease.... |
 | The Development of Human Gene Therapy (Cold Spring Harbor Monograph Series) The idea of human gene therapy was accepted by the medical community and society at large long before believable clinical benefits began to emerge. In this book, some of the field’s most distinguished contributors chronicle the evolution of this momentous direction for medicine, illustrating how imaginative concepts shaped the development of technologies and brought the daring new idea to its... |
 | Understanding Gene Therapy (Medical Perspectives) by Prof Ni Lemoine What is gene therapy? How are genes delivered? Which diseases can be treated? What is the status of current clinical trials? What are the ethical issues? What are the future prospects? Understanding Gene Therapy answers all these questions and more, providing an ideal introduction to this complex and rapidly developing field. Written and edited by leading experts, the book provides a highly... |
 | Stem Cell and Gene-Based Therapy: Frontiers in Regenerative Medicine The inability of the human body to be able significantly to self repair injured organs and tissues results in a considerable medical and social problem. During the last few years there has been incredible progress, and the achievements in experimental strategies for tissue regeneration, particularly in cell transplantation and stem cell research, have led to potential treatment options for many... |
 | The Ethics of Human Gene Therapy by LeRoy Walters, Julie Gage Palmer The authors of this absorbing new book describe the science of gene therapy in terms easily accessible to the non-specialist, and focus on the controversial ethical and public policy issues surrounding human interventions in human heredity. After a brief survey of the structure and functions of DNA, genes, and cells, Walters and Palmer discuss three major types of potential genetic intervention:... |
 | Polymeric Gene Delivery: Principles and Applications To treat disease or correct genetic disorders using gene therapy, the most suitable vehicle must be able to deliver genes to the appropriate tissues and cells in the body in a specific as well as safe and effective manner. While viruses are the most popular vehicles to date, their disadvantages include toxicity, limited size of genes they can carry, and limited scale of industrial production. ... |
 | Gene Therapy for Cancer (Cancer Drug Discovery and Development) The possibility of treating cancer, a disease frequently defined bygenetic defects, by introducing genes that target these veryalterations has generated tremendous enthusiasm. This enthusiasm,however, has been tempered by an increasing number of obstacles tosuccessful therapy, including vector systems that do not reach systemicmetastases, therapeutic genes with redundant mechanisms allowing... |
 | W. French Anderson: Father of Gene Therapy (Oklahoma Trackmaker Series) by Bob Burke, Barry Epperson This is the story of Dr. W. French Anderson who performed the first government-approved human gene transfer in 1990 on a patient stricken with a deadly disease from birth. Anderson has brought humanity into a fourth revolution of medicine, healing disease by genetic engineering. Anderson is a Tulsa, Oklahoma, native who currently is the director of the Gene Therapy Laboratories at the... |
| © 2008 BrightSurf.com |